UK markets open in 2 hours 1 minute

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
224.11+0.19 (+0.08%)
At close: 04:00PM EST
224.50 +0.39 (+0.17%)
After hours: 07:29PM EST
Sign in to post a message.
  • R
    Playing with fire. BIIB spiked 3 different time each being higher than the previous. It's spiked Feb 2020 at $376, then Nov 2020 then June 2021 at $471. Bears definitely got caught in a trap. Not sure how's this will play out, but one day I hope they get the Alzheimer's drug correct. My Mom passed away from this terrible disease.
  • V
    Another new low. Makes you wonder whether stockholders wouldn't have been better off, if the FDA had put thumbs down on Aduhelm...
  • D
    I've been flipping this stock successfully for 2 years now. Buy low sell high, rinse and repeat. They have a pipeline but the wall street shorting machine fuds them down to pop them every time to then fud them down again. I'll be accumulating to flip again since they are not going out of business
  • L
    Pleased to report that the shares I sold at $459 I have purchased back today at $227. Good ole Biogen. One of the best trading stocks out there!
  • V
    Good news about Zuranolone, which could potentially be a big deal drug and the stock drops to another... new low... geesh.
  • s
    Medicare just declared a premium? Does this mean they are readying to approve Aduhelm. I think the evidence is clear. Better to get on this drug and halt the disease till something better comes a long.
  • V
    At present truly as basket case. Tax-loss selling?
  • B
    Averaged down to $270/sh using covered calls. Hope we eventually get back to ~ $300. Good luck to all the longs.
  • D
    NY Times: Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drug -- Newly published safety data shows that 41 percent of patients in key clinical trials of the Alzheimer’s drug experienced brain bleeding or swelling, though many cases were asymptomatic
  • A
    November 9, 2021 02:08 PM EST PharmaMarketing
    The very slow roll of Biogen's Aduhelm: Neurologists weigh in on patients, practices and payments amid ongoing media storm

    Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a laundry list of ongoing woes including insurance reimbursement uncertainty, dismal initial sales, a label flipflop, FDA advisory committee members resigning and outspoken researchers and public officials who continue to question the drug’s approval.

    To say that Aduhelm has an image problem is an understatement. The Biogen drug was not only one of the biggest newsworthy drug approvals of 2021 as a supposed first-ever treatment for the root cause of Alzheimer’s disease, but also the most controversial in recent years.

    Yet despite the daily downpour, neurologists on the ground are infusing. Not in the numbers Biogen initially promised or that analysts expected, but in numbers that are keeping some practices busy. Neurologist Stephen Salloway now counts 20 patients under care and is adding two new patients every week. He dosed the first patient in the US with Aduhelm at Butler Hospital in Providence, RI in June after having served as a site leader for Biogen’s ENGAGE aducanumab trial.

    Despite a “large backlog of interest from people inquiring from around the world,” Salloway is purposefully rolling Aduhelm slowly. “You know, there are issues with the drug in terms of the approval and the controversy and everything,” he said. “Patients and families have to weigh, given the potential benefits and the potential risk and the insurance issues, is it right for them? We spent a lot of time talking with patients and families about that and helping them make the decision that’s right for them.”

    Jeffrey Gelblum, neurologist at First Choice Neurology in Florida, tells a similar story. He was the first in Florida to deliver an Aduhelm infusion to a patient — a middle-aged woman with early onset Alzheimer’s — also in June. Now he’s treating 30 patients and estimates as many as 80 people are receiving Aduhelm across the First Choice Neurology practice. His group also has more demand than available capacity, he said.

    “I’m talking with you on a Sunday for one major reason. I’m busy Monday through Friday. I’m busy taking care of patients,” Gelblum said. One misconception both doctors agreed on is that Aduhelm patients are mostly paying out of pocket for the treatment. Some private insurances are paying — Gelblum said Aetna and Cigna have both paid with proper prior authorization and follow-up documentation. So is Medicare, although for now on a case-by-base regional basis.

    The Centers for Medicare & Medicaid Services (CMS) announced in July it had begun weighing the national Medicare coverage policy for monoclonal antibodies targeting amyloid for the treatment of Alzheimer’s disease, which includes Aduhelm. CMS promised an initial determination in January, followed by a final decision in April. While Medicare takes comments and weighs its decisions, the 12 CMS offices around the US are making regional decisions on paying for Aduhelm treatment. But it’s not an easy process.

    Salloway said, “We have focused initially on people that have Medicare as a primary with a supplementary insurance. And we submit those bills to our local Medicare provider and the supplement and we have had some positive responses. But it’s a cumbersome process. And there are a lot of delays.” One bright spot has been the relative ease of establishing a clinical process to evaluate, prescribe, infuse and follow patients. Like other Aduhelm infusers, the neurologists are only treating people diagnosed with mild cognitive impairment or early Alzheimer’s.

    With the approval now sealed and others on the way, he added, “We’ve really come to a new phase in the cause.” That new phase includes continuing to raise awareness and pushing for federal funding support but also helping doctors and hospitals prepare for treatments with things like screening tools. Looking even further into the future, the association sees a time in the future when Alzheimer’s disease get a broad health approach that includes lifestyle recommendations for nutrition, exercise, community engagement or the value of lifelong learning similar to the add-ons that have happened in cardiovascular disease.

    While Salloway is sanguine about the way the approval and rollout is playing out in the media, Gelblum is feisty. Salloway says he understands why people have been critical, but Gelblum dismisses them as unfairly negative or maybe just trying to get attention. Salloway said, “I wish a lot of things were different. “I’m proud to say I’ve done my Alzheimer’s research, but my first focus is always on what’s best for the patient, what’s most efficacious and what can I offer that patient now?
  • b
    SAVA will take over the Alzheimer's drugs very soon, check the news there. BIIB needs to acquire SAVA now!
  • R
    The reason I bought BIIB. This stock is crazy. Shorts get trapped every time then the stock ends up 200 points in one day. The last time it popped was at $235 per share. Does history repeats? I say yessss.
  • I
    I believe this is a very worthwhile development for people who might need treatment:

    "Alzheimer's disease may be detectable by key blood test, study finds
    Fri, November 12, 2021, 4:50 PM
    A new blood test may identify more than 80% of people with increased likelihood of having amyloid in the brain, a protein that’s a risk factor for developing Alzheimer’s disease, according to a recent study that was presented this week at Boston’s international Clinical Trials on Alzheimer’s Disease conference.

    In patients with Alzheimer’s disease, the amyloid protein clumps together to form plaques that collect between neurons to disrupt cellular function, according to the National Institute of Health (NIH).

    Because these plaques accumulate in patients’ brains before the signs and symptoms appear of Alzheimer’s disease, a positron emission tomography (PET) scan is traditionally ordered to identify those at most risk, according to a recent report.

    C₂N Diagnostics, however, developed a blood test called PrecivityAD that accurately predicts the level of amyloid that was on a PET scan 81% of the time.

    "Blood-based screening is a giant leap forward in detecting changes in the brain among people who do not yet show memory loss symptoms," said Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and co-principal investigator for the study, according to a statement.

    The blood test will be used for the first time in a clinical trial with the goal of preventing the symptoms of Alzheimer's disease in a study called the AHEAD study, according to a report.

    "The AHEAD Study tests whether an investigational treatment can slow or stop the earliest brain changes due to Alzheimer’s disease in people with a higher risk of developing the disease later in life," according to the study’s website.

    Dr. Sperling notes another goal is to recruit a diverse population of participants hoping the screening blood test will lower barriers to participate in the study because people of color are often underrepresented in Alzheimer trials."
  • B
    I remain short from 400+, and not planning to cover over $200, may be 175 on slide.
  • E
    $RLFTF conversation
    Found this post by SAVAge on Eli Lilly on Breakthrough Therapy Designation/ BTD approvals from a couple months ago showing that BTD led to $15B market cap increases in a single day ... I believe in the cases notes for treatments for Alzheimer’s.

    Not sure if we could get that kind of pop ... but I found the info interesting.

    Hoping Dr J can get the BTD approval for Aviptadil

    On Monday, June 7th, $BIIB announced FDA Accelerated Approval of its Alzheimer's medication. The market cap increased by $17 billion.

    On June 24th, $LLY announced FDA Breakthrough Therapy Designation of Their Alzheimer's medication. The market cap increased by $15 billion.

    Last Friday, Roche announced the FDA Breakthrough Therapy Designation of its Alzheimer's medication. Its market cap increased by $13 billion.

    SAVA's Market cap sits at $2 billion. If the market cap increases by the Median ($15 billion), the SP will 8.5x.

    Oh, did I mention the above changes happened on ONE trading day? It did. Full post on FDA approval odds linked below.
  • R
    In a pre-specified analysis, ADUHELM significantly lowered plasma p-tau181, a biomarker of the hallmark tau tangles in Alzheimer’s disease, in both Phase 3 trials in a dose- and time-dependent manner vs. placebo
  • c
    Down 4% because a 64 year old head of R&D retiring?

    Lol what? That guy was worth 2 billion in market cap? Haha. Buy the dip.
  • s
    Biogen shot themselves in the foot with the high price. Did they not know donanemab from Lily was around the corner- I did. Why did they price it so high.

    35000 a year might have made this a far more successful venture than 56000.

    Do we really think at the point the EU is really uncertain of efficacy or concerned about price as their systems are pretty bankrupt anyway!

    Biogen screwed themselves with the price.
  • k
    As I stated a few weeks ago, ( not bragging) just do my homework / research. Adulhelm does work and lowers the tau / amyloid. Great news just released.
    The company is starting to see significant improvement in selling (helping people with beginning stages.).
    Buy 425 March / April
  • k
    kevin w
    Vumerity on track for 500 million in annual revenue and they are on track for royalty revenues from Roche Ocravis to the tune of 1 billion revenue. Biosimilars 2-300 million. Antisense ~1 billion. not going to 150 or 200. 250 is bottom not top. Aduhelm is gravy if it persists.